12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lipitor atorvastatin regulatory update

FDA approved a generic version of marketed drug Lipitor atorvastatin from Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359, Gurgaon, India) after the Pfizer cholesterol therapy lost market exclusivity on Nov. 30. Ranbaxy, which immediately launched the product, now has 180...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >